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1 Despitethespectacularsuccessofanti-PD1therapy,itsefficacy is limited to only a subset of patients. 4, 6, 7 Multiple studies indicate that treatment is effective in patients in which a pre-existing CD8 + T-cellresponseissuppressedbythePD1-PDL1axis. [8] [9] [10] Hence,tumor microenvironments (TMEs) that activate, attract, and maintain CD8 + T cells favor clinical response to checkpoint inhibitors. 11, 12 Notably, innateimmunecellsmediatetheactivationandrecruitmentofTcells. CoupledwiththeirprominentpresenceintheTME,theindispensable functionofinnatecellsintheinductionandmaintenanceofadaptive immunity provides an impetus for investigating their role in shaping theresponseagainstcancer.LikeTcells,innateimmunecellsalsoexpresscheckpointmoleculesthatinhibittheiractivityandlimitengagementofadaptiveimmunity.Thisreviewwillfocusonafamilyofinnate immuneinhibitoryreceptors,comprisedofTYRO3,AXL,andMERTK (TAMs), and will discuss their emerging role as novel candidates for checkpointblockade. Malignant cells can express many antigens that can be recognized by tumor-infiltratingT cells (TILs).
| INNATE IMMUNE CHECKPOINTS AS TARGETS OF CANCER IMMUNOTHERAPY
A
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Neoantigens generated by somatic point mutations are thought to be ideal targets for initiatingTILactivity. 18, 19 Sincetheyarenotsubjecttocentraltolerance, neoantigens can be 'seen' by T cells. This recognition is, of course, reliantontheacquisitionandpresentationofsaidantigensbymajor histocompatibility complexes (MHCs) on the surface of APCs. 
| TAM RTKS
TheTAMRTKs,TYRO3,AXL,andMERTKhaveapivotalroleinhomeostatic regulation of the immune system. These receptors were first identified as a distinct RTK subfamily, in a screen for RTKs expressedinSchwanncells. Bothligandscontaingamma-carboxylated glutamic acid (Gla) residues near their N-terminal domains. GammacarboxylationoftheGladomainenablesbindingtophosphatidylserine (PtdSer). 53 Maximal bioactivity of both GAS6 and PROS1 is dependentongamma-carboxylationandPtdSerbinding. [54] [55] [56] [57] Hence, these ligands function as bridges in a tripartite arrangement involvingaPtdSer-exposingcellandaTAMreceptor-bearingcell.Although these ligands share the same structural motifs, they differ in some of their functions and receptor specificities. PROS1 was isolated as the active component of adult bovine aortic endothelial (ABAE) cell line-conditionedmedia.PROS1phosphorylatedTYRO3,whileABAEderivedGAS6wasidentifiedasanAxlagonist.
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Albeitwithdifferent affinities, GAS6 was later found to bind and activate all three TAM receptors (AXL≥TYRO3»MER). While this negative regulatory system is decidedly important to avoidtheaberranteffectsofunreinedinflammation,therealsoneeds tobeamechanismthattriggersitonlyafterinnateimmunecellshave sufficiently activated adaptive immunity. Indeed, our group demonstratedthatsuchanelegantfeedbackloopmechanism exists. 69 The
TAMligandPROS1isexpressedinbothmouseandhuman-activated, butnotresting,Tcells. 69, 70 SelectivedeletionofTcell-derivedPROS1
enhanced APC activation and cytokine production in an antigenspecific, TAM RTK-dependent manner. 69 Furthermore, in a model ofT-cell induced colitis, the transfer of PROS1-deficientT cells into
Rag1
−/− recipients accelerated colitis. 69 Importantly, this mechanism is conserved in humans. In mixed lymphocyte reactions, antibodymediatedblockadeofhumanPROS1resultedinincreasedactivation ofhumanDCs. 69 Overall,thesedataindicatedthatthePROS1-TAM signaling axis functions at the interface of innate and adaptive immunitytorestraintheactivityofinnatecellsandultimatelycurbunwantedconsequencesofinflammation.
YetanothersubsetofcellsregulatedbytheTAMsareNKcells.
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Activating and inhibitory receptors present on the surface of NK cells direct recognition and killing of target cells. These receptors are acquired as an NK cell transitions through various stages of differentiation.
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Bone marrow-derived stromal cells release PROS1
andGAS6toactivatetheTAMRTKspresentonimmatureNKcells.
In the absence of TAM receptor signaling, these immature NK cells do not acquire expression of the activating and inhibitory receptors required for late NK cell differentiation. It is also entirely possible that theTAM receptors mediate efferocytosis through PtdSer-independent mechanisms. In addition to the cognate agonists PROS1 and GAS6, the 'eat-me' signals galectin-3 (Gal-3), tubby, and tubby-like protein 1 (Tulp1)were identified asligandsofMERTKthatfacilitatephagocytosisofACs.
| MECHANISMS UNDERLYING INNATE CHECKPOINT FUNCTION OF TAMS
| Efferocytosis
112,113
While Tulp1bindstoallthreeTAMRTKs,Gal-3andtubbyexclusivelybind toMERTK. 112, 113 Caberoyetal.alsofoundthattubbyandTulp1in-teractwithMERTKthroughanN-terminaldomainandbinddeadcells through their C-terminal phagocytosis prey-binding domain (PPBD). 
| Negative regulation of DC function
TLR engagement triggers proinflammatory cytokine production and significantly upregulates TAM RTK expression on BMDCs, in vitro. Addition of recombinant TAM ligands, PROS1 and GAS6, was also shown to suppress activation of DCs and shut down cytokine production.
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Specifically,signalsdownstreamofTLRengagementled totheproductionoftypeIIFNs,whichinturninducedAxlmRNAupregulation.
Onceactivated,TAMsignalingtriggeredexpressionofthe suppressorofcytokinesignalingproteins,SOCS1andSOCS3. 
| Reprogramming of migratory cues
SuccessfulrecruitmentandretentionofnaiveandeffectorTcellsinany tissue,includingtheTME,requiresproductionofvariouschemokine molecules by innate and stromal cells. Not surprisingly, melanoma patientsamplesthathaveTcellspresentalsoexpresstranscriptsof chemokinesrelatedtoT-cellrecruitment.Insharpcontrast,samples
withlimitedT-cellinfiltrationlackedexpressionofmanychemokines including CCL2, CCL3, CCL4, CCL5, CXCL9, and CXCL10. 11, 120 Inability to produce these chemokines can be a barrier to effective T-cell-drivenkillingoftumorcells.Indeed,inmousemodels,transplantationofmelanomacellsexpressingtheseT-cell-attractingchemokines resultedinCD8 + T-cellrecruitmentintotumors. Currently,ananalogousTAM-basedregulationofchemokineproductionhasnotbeenreportedininnateimmunecellsoftheTME.
Of interest, a similar function of reprogramming migratory cues has indeed been described for theTAMs in a non-immune context.
MERTKknockdowninbreastcancercellsnon-cell-autonomouslyinhibited metastatic endothelial cell migration. 
| TAMS AS THERAPEUTIC TARGETS
